prof. MUDr. Ľudmila Podracká, PhD.
Vedecko/umelecko-pedagogická charakteristika:
Najvýznamnejšie výstupy tvorivej činnosti:
1. | Chromek M, Slamová Z, Bergman P, Kovács L, Podracká L, Ehrén I, Hökfelt T, Gudmundsson GH, Gallo RL, Agerberth B, Brauner A. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nature Medicine. 2006 | Q1 | IF 28,588 |
2. | Gee HY, Zhang F, Ashraf S, Kohl S, Sadowski CE, Vega-Warner V, Zhou W, Lovric S, Fang H, Nettleton M, Zhu JY, Hoefele J, Weber LT, Podracka L, Boor A, Fehrenbach H, Innis JW, Washburn J, Levy S, Lifton RP, Otto EA, Han Z, Hildebrandt F. KANK deficiency leads to podocyte dysfunction and nephrotic syndrome. Journal of Clinical Investigation. 2015 | Q1 | IF 12,575 |
3. | Vidal E, van Stralen KJ, Chesnaye NC, .......; ESPN/ERA-EDTA Registry including Podracká, Ľ: Infants requiring maintenance dialysis: Outcomes of hemodialysis and peritoneal dialysis. American Journal of Kidney Diseases. 2017 | Q1 | IF 7,129 |
4. | Male C, Lensing AWA, Palumbo JS, .........; EINSTEIN-Jr Phase 3 Investigators. including Podracká, Ľ: Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. The Lancet Haematology 2020. | Q1 | IF 18,959 |
5. | Garam N, Cserhalmi M, Prohászka Z, .............., Podracka L, ................. FHR-5 serum levels and CFHR5 genetic variations in patients with immune momplex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy. Frontiers in Immunology. 2021. | Q1 | IF 7,561 |